Works by Nowakowski, Grzegorz S.
Results: 86
T cell/histiocyte‐rich large B cell lymphoma: incidence, demographic disparities, and long‐term outcomes.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 140, doi. 10.1111/bjh.15391
- By:
- Publication type:
- Article
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00942-3
- By:
- Publication type:
- Article
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00847-1
- By:
- Publication type:
- Article
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00847-1
- By:
- Publication type:
- Article
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00649-x
- By:
- Publication type:
- Article
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00598-x
- By:
- Publication type:
- Article
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00542-z
- By:
- Publication type:
- Article
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 7, p. 1, doi. 10.1038/s41408-021-00525-0
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00394-z
- By:
- Publication type:
- Article
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00382-3
- By:
- Publication type:
- Article
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0233-5
- By:
- Publication type:
- Article
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0208-6
- By:
- Publication type:
- Article
Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 2, p. 116, doi. 10.1016/j.clml.2024.07.019
- By:
- Publication type:
- Article
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e815, doi. 10.1016/j.clml.2022.04.009
- By:
- Publication type:
- Article
MCL-042: Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S408, doi. 10.1016/S2152-2650(21)01919-4
- By:
- Publication type:
- Article
ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S392, doi. 10.1016/S2152-2650(21)01891-7
- By:
- Publication type:
- Article
ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S376, doi. 10.1016/S2152-2650(21)01860-7
- By:
- Publication type:
- Article
Poster: MCL-042: Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S246, doi. 10.1016/S2152-2650(21)01551-2
- By:
- Publication type:
- Article
Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01533-0
- By:
- Publication type:
- Article
Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01499-3
- By:
- Publication type:
- Article
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy.
- Published in:
- Clinical Epidemiology, 2019, v. 11, p. 987, doi. 10.2147/CLEP.S219595
- By:
- Publication type:
- Article
Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia.
- Published in:
- British Journal of Haematology, 2005, v. 128, n. 4, p. 490, doi. 10.1111/j.1365-2141.2004.05341.x
- By:
- Publication type:
- Article
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
- Published in:
- Annals of Hematology, 2023, v. 102, n. 7, p. 1773, doi. 10.1007/s00277-023-05196-4
- By:
- Publication type:
- Article
RNAseq identification of FISH‐cryptic BCL6::TP63 rearrangement in ALK‐negative anaplastic large‐cell lymphoma.
- Published in:
- Histopathology, 2022, v. 81, n. 2, p. 275, doi. 10.1111/his.14674
- By:
- Publication type:
- Article
Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
- Published in:
- JAMA Network Open, 2020, v. 3, n. 8, p. e2012534, doi. 10.1001/jamanetworkopen.2020.12534
- By:
- Publication type:
- Article
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?
- Published in:
- Nutrition & Cancer, 2018, v. 70, n. 7, p. 1088, doi. 10.1080/01635581.2018.1502328
- By:
- Publication type:
- Article
T cell/histiocyte‐rich large B cell lymphoma: incidence, demographic disparities, and long‐term outcomes.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 1, p. 140, doi. 10.1111/bjh.15391
- By:
- Publication type:
- Article
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 149, doi. 10.1111/bjh.14922
- By:
- Publication type:
- Article
Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 5, p. 644, doi. 10.1111/bjh.15416
- By:
- Publication type:
- Article
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 50, doi. 10.1111/bjh.14813
- By:
- Publication type:
- Article
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 3, p. 427, doi. 10.1111/bjh.14688
- By:
- Publication type:
- Article
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 3, p. 321, doi. 10.1111/j.1365-2141.2012.09067.x
- By:
- Publication type:
- Article
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 1, p. 53, doi. 10.1111/j.1365-2141.2011.08794.x
- By:
- Publication type:
- Article
Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 3, p. 402, doi. 10.1111/j.1365-2141.2010.08514.x
- By:
- Publication type:
- Article
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
- Published in:
- British Journal of Haematology, 2009, v. 147, n. 4, p. 471, doi. 10.1111/j.1365-2141.2009.07868.x
- By:
- Publication type:
- Article
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 1, p. 39, doi. 10.1002/hon.3098
- By:
- Publication type:
- Article
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 658, doi. 10.1002/hon.2919
- By:
- Publication type:
- Article
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 210, doi. 10.1111/bjh.17691
- By:
- Publication type:
- Article
Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 6, p. 820, doi. 10.1111/bjh.15997
- By:
- Publication type:
- Article
The Richardson/Schlossman/Hideshima et at Article Reviewed.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 14, p. 1796
- By:
- Publication type:
- Article
Holistic review for hematology‐oncology fellowship applicants: A new paradigm?
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. 1124, doi. 10.1002/ajh.25930
- By:
- Publication type:
- Article
Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. 786, doi. 10.1002/ajh.25493
- By:
- Publication type:
- Article
Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 3, p. 291, doi. 10.1002/ajh.25350
- By:
- Publication type:
- Article
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1156, doi. 10.1002/ajh.24864
- By:
- Publication type:
- Article
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 5, p. 448, doi. 10.1002/ajh.24671
- By:
- Publication type:
- Article
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 5, p. 467, doi. 10.1002/ajh.24693
- By:
- Publication type:
- Article